Vericel Co. (NASDAQ:VCEL) Insider Sean C. Flynn Sells 1,474 Shares

Vericel Co. (NASDAQ:VCEL) insider Sean C. Flynn sold 1,474 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $45.84, for a total transaction of $67,568.16. Following the completion of the sale, the insider now directly owns 487 shares in the company, valued at approximately $22,324.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Vericel Trading Up 1.9 %

Shares of NASDAQ VCEL opened at $45.76 on Thursday. Vericel Co. has a 12 month low of $30.18 and a 12 month high of $53.05. The stock has a 50 day moving average of $46.49 and a 200-day moving average of $44.38. The company has a market capitalization of $2.22 billion, a P/E ratio of -4,571.43 and a beta of 1.74.

Vericel (NASDAQ:VCEL) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The business had revenue of $51.28 million during the quarter, compared to the consensus estimate of $49.07 million. During the same quarter in the previous year, the firm posted ($0.16) EPS. Vericel’s revenue was up 25.0% compared to the same quarter last year. Analysts predict that Vericel Co. will post 0.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Vericel

Hedge funds and other institutional investors have recently modified their holdings of the company. Congress Asset Management Co. MA boosted its stake in shares of Vericel by 509.1% in the first quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock valued at $43,514,000 after buying an additional 699,147 shares during the period. TimesSquare Capital Management LLC acquired a new stake in shares of Vericel during the first quarter worth $12,782,000. Comerica Bank grew its holdings in Vericel by 61,063.9% during the 3rd quarter. Comerica Bank now owns 208,569 shares of the biotechnology company’s stock worth $6,991,000 after acquiring an additional 208,228 shares during the period. Geneva Capital Management LLC grew its stake in Vericel by 43.6% during the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock worth $35,330,000 after purchasing an additional 206,202 shares during the period. Finally, FMR LLC grew its position in shares of Vericel by 39.5% during the 3rd quarter. FMR LLC now owns 571,298 shares of the biotechnology company’s stock worth $19,150,000 after buying an additional 161,652 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on VCEL shares. TD Cowen initiated coverage on shares of Vericel in a research report on Thursday, June 20th. They set a “buy” rating and a $55.00 price target on the stock. HC Wainwright upped their target price on Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Friday, June 21st. Finally, Truist Financial reaffirmed a “buy” rating and set a $54.00 price target on shares of Vericel in a research report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.17.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.